Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 5Completed 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Lymphoid 5

Conditions

Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 8Recurrence 7Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Lymphoma 4Dendritic Cell Sarcoma, Interdigitating 2Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Cytokine Release Syndrome 1Aggression 1

Interventions

Cyclophosphamide 22fludarabine 15Rituximab 11Immunotherapy, Adoptive 10Specimen Handling 8Vincristine 7Prednisone 7Magnetic Resonance Spectroscopy 7Doxorubicin 7Etoposide 6Biopsy 6glofitamab 5zanubrutinib 4polatuzumab vedotin 4obinutuzumab 4Lenalidomide 4Bendamustine Hydrochloride 4relmacabtagene autoleucel 3loncastuximab tesirine 3fludarabine phosphate 3axicabtagene ciloleucel 3Leukapheresis 3Ifosfamide 3Carboplatin 3tafasitamab 2etoposide phosphate 2X-Rays 2Nivolumab 2Injections 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, B-Cell × glofitamab × Clear all
NCT06634589 2026-05-11

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

ADC Therapeutics S.A.

Phase 1 Recruiting
200 enrolled
Lymphoid

Lymphoma, B-Cell

NCT06393738 2026-02-10

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Arvinas Inc.

Phase 1 Recruiting
255 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT06213311 2026-01-14

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

NCT06497452 2024-07-11

GLOFTST

The First Affiliated Hospital of Soochow University

Recruiting
50 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡